婴儿配方粉健康与营养声称:国际横断面调查
该国际横断面调查于2020-22年评估15国婴儿配方粉网站上的健康与营养声称及其证据。共识别757个产品,多数产品至少有一项声称,但仅26%提供科学文献支持,且被引临床试验和系统综述多存在高偏倚风险。
要点
- 757个婴儿配方粉产品中,608个有至少一项声称,常见为支持脑眼神经发育、免疫和生长发育。
- 仅26%(161/608)有声称的产品提供了科学文献,共引用266篇文献。
- 被引临床试验中仅28%注册,90%的随机对照声称证据存在高偏倚风险。
核心结论
- 多数婴儿配方粉产品至少有一项健康或营养声称,但许多声称缺乏特定成分引用,且被引证据不支持声称的稳健性。
研究设计与样本
- 国际横断面调查,于2020-22年检索15国面向公众和医疗专业人员的配方粉行业网站,纳入足月健康婴儿产品。
主要发现
- 共识别757个产品,每个产品中位声称数为2项(范围从澳大利亚的1项到美国的4项),所有产品共31种声称类型。
- 608个有至少一项声称的产品中,最常见声称类型为「帮助/支持脑和/或眼和/或神经系统发育」(323个产品,53%,涉及13种成分),「增强/支持健康免疫系统」(239个产品,39%,涉及12种成分),「帮助/支持生长发育」(224个产品,37%,涉及20种成分)。
- 41组成分与至少一项声称相关,但307个产品(50%)的声称未引用特定成分。
- 声称中最常引用的成分类别为长链多不饱和脂肪酸(278个产品,46%,9种不同声称)、益生元/益生菌/合生元(225个产品,37%,19种声称)和水解蛋白(120个产品,20%,9种声称)。
- 161/608个产品(26%)提供了科学文献支持声称,共引用266篇独特文献,涉及24种声称类型;引用类型最常见为临床试验(50%,134/266)和综述(20%,52/266)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To review available health and nutrition claims for infant formula products in multiple countries and to evaluate the validity of the evidence used for substantiation of claims. DESIGN: International cross sectional survey. SETTING: Public facing and healthcare professional facing company owned or company managed formula industry websites providing information about products marketed for healthy infants delivered at full term in 15 countries: Australia, Canada, Germany, India, Italy, Japan, Nigeria, Norway, Pakistan, Russia, Saudi Arabia, South Africa, Spain, the United Kingdom, and the United States in 2020-22. MAIN OUTCOME MEASURES: Number and type of claims made for each product and ingredient. References cited were reviewed and risk of bias was assessed for registered clinical trials using the Cochrane risk of bias tool, and for systematic reviews using the Risk Of Bias in Systematic reviews tool. RESULTS: 757 infant formula products were identified, each with a median of two claims (range from 1 (Australia) to 4 (US)), and 31 types of claims across all products. Of 608 products with ≥1 claims, the most common claim types were "helps/supports development of brain and/or eyes and/or nervous system" (323 (53%) products, 13 ingredients), "strengthens/supports a healthy immune system" (239 (39%) products, 12 ingredients), and "helps/supports growth and development" (224 (37%) products, 20 ingredients). 41 groups of ingredients were associated with ≥1claims, but many claims were made without reference to a specific ingredient (307 (50%) products). The most common groups of ingredients cited in claims were long chain polyunsaturated fatty acids (278 (46%) products, 9 different claims); prebiotics, probiotics, or synbiotics (225 (37%) products, 19 claims); and hydrolysed protein (120 (20%) products, 9 claims). 161/608 (26%) products with ≥1 claims provided a scientific reference to support the claim-266 unique references were cited for 24 different claim types for 161 products. The reference types most frequently cited were clinical trials (50%, 134/266) and reviews (20%, 52/266). 28% (38/134) of referenced clinical trials were registered, 14% (19/134) prospectively. 58 claims referred to 32 registered clinical trials, of which 51 claims (27 trials) related to a randomised comparison. 46 of 51 claims (90%) referenced registered clinical trial outcomes at high risk of bias, and all cited systematic reviews and pooled analyses, carried a high risk of bias. CONCLUSIONS: Most infant formula products had at least one health and nutrition claim. Multiple ingredients were claimed to achieve similar health or nutrition effects, multiple claims were made for the same ingredient type, most products did not provide scientific references to support claims, and referenced claims were not supported by robust clinical trial evidence.
引用
- Cheung KY, Petrou L, Helfer B, et al. Health and nutrition claims for infant formula: international cross sectional survey. BMJ. 2023. PMID: 36792145. doi:10.1136/bmj-2022-071075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。